Mournier et al identified prognostic factors for patients with aggressive non-Hodgkin's lymphoma who were treated with autologous stem cell transplantation (ASCT). This can help identify patients who may require more aggressive management and closer monitoring. The authors are from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Prognostic factors:
(1) number of extranodal sites
(2) bone marrow involvement
(3) histologic type of lymphoma
(4) type of anthracycline used for chemotherapy
Parameter |
Finding |
Points |
number of extranodal sites |
0 or 1 |
0 |
|
>= 2 |
1 |
bone marrow involvement |
absent |
0 |
|
present |
1 |
histologic type |
nonanaplastic T cell |
1 |
|
other |
0 |
type of anthracycline used |
mitoxantrone |
0 |
|
doxorubicin |
1 |
number of risk factors for decreased disease free survival (increased risk for relapse) =
= SUM(points for all 4 parameters)
number of risk factors for decreased overall survival =
= (points for extranodal sites) + (points for bone marrow involvement) + (points for histologic type)
Interpretation:
• minimum number of risk factors: 0
• maximum number of risk factors for disease free survival: 4
• maximum number of risk factors for overall survival: 3
Specialty: Hematology Oncology, Surgery, general